Medicines Financial News

Subscribe to enjoy similar stories.New Delhi: The Centre is weighing an emergency, one-time increase in prices of around 300 essential medicines as the West Asia war disrupts supplies of petrochemical-based pharmaceutical inputs and drives up manufacturing costs, according to two government officials and two industry executives.The increase, which is being discussed between the National Pharmaceutical Pricing Authority (NPPA), the Department of Pharmaceuticals (DoP), and the commerce ministry, would be rolled back once supply chains stabilize, they said.The medicines under discussion include antibiotics and anti-infectives (amoxicillin, azithromycin), cardiac drugs (amlodipine, atorvastatin), and analgesics (paracetamol), besides other essential and life-saving formulations such as steroids (dexamethasone) and vitamins (ascorbic acid) that are dependent on imported active pharmaceutical ingredients and petrochemical-based solvents.“A proposal has come from the industry to the government regarding this pricing, and the government is reviewing the matter,” one of the two officials cited above said, requesting anonymity.“Indian Drugs Manufacturing Association (IDMA) is in dialogue with the government for getting some temporary relief under Drugs Prices Control Order (DPCO), in order to ensure a balance between the industry concerns and patients’ needs,” said Dr.

Subscribe to enjoy similar stories.Apollo Hospitals Enterprise Ltd (AHEL), the country’s largest listed hospital chain by beds, is betting on its planned capacity expansion as well as its clinical programmes and expertise to maintain its lead in an increasingly competitive private healthcare market, its top management said.The hospital chain, which commissioned four hospitals in Pune, Kolkata, Hyderabad and Delhi in FY26, plans to add about 1,500 beds in the next 12-18 months. This includes beds in the new hospitals as well as existing ones.“We think capacity is a strategically important lever… it will place us as the largest player substantially in terms of bed capacity.

Subscribe to enjoy similar stories.A nationwide pharmacy strike planned for 20 May has been severely weakened after retailer associations in 12 major states, including West Bengal, Maharashtra and Uttar Pradesh, withdrew their support. The pullout followed a decision by the Central Drugs Standard Control Organisation (CDSCO), the national drug regulator, to review retail and online pharmacy operations, according to two officials familiar with the matter, who requested anonymity.The All India Organisation of Chemists and Druggists (AIOCD), representing over 1.2 million retailers, had called for the shutdown to protest the unregulated growth of e-pharmacies.

Subscribe to enjoy similar stories.NEW DELHI: The Centre is preparing to crack down on the illegal sale, distribution and misuse of sexual enhancement medicines, with the drug regulator warning that it has become a threat to both public safety and social dignity, according to two government officials and a document reviewed by Mint.This regulatory action against unauthorized products sold without valid prescriptions has been ordered by Drugs Controller General of India (DCGI) Dr. Rajeev Singh Raghuvanshi.

Subscribe to enjoy similar stories.Indian pharma stocks are attracting foreign institutional investors (FIIs) due to their strong export orientation, especially in regulated markets like the US, and consistent demand for generics and speciality drugs.Companies are benefiting from cost advantages, improving compliance records, and a growing focus on complex formulations and APIs.Additionally, defensive characteristics during global uncertainty make pharma appealing. Here are three pharma stocks where FIIs have hiked their stake in the March 2026 quarter.Shilpa Medicare is a niche Indian pharma company focused on oncology APIs, complex formulations, and CDMO services.

Subscribe to enjoy similar stories.Initially, Navin Israni, 36, didn’t treat his back pain as much as he furnished around it. A back-support cushion for his work chair, then a medicine ball he tried sitting on and returned for being too large—both ordered online. The cushion on his sofa moved up to act as back support, then a sheet of plywood affixed to provide a firm seat.

Subscribe to enjoy similar stories.New Delhi: India has issued guidelines defining and classifying intensive care units (ICUs), a regulatory step that will affect 71,000 hospitals and over 1.38 million registered doctors in the country, as the government aims to eliminate hospital-acquired infections and address uneven critical care standards, according to an official familiar with the matter and a document reviewed by Mint.The directorate general of health services (DGHS), operating under the health and family welfare ministry, has categorized ICUs into three levels. The standards start at Level 1 units that are intended for basic stabilization with a minimum of six beds and one ventilator, to Level 3 units equipped for advanced multi-organ failure support with bedside portable CT and mobile digital radiography.The norms set round-the-clock physician coverage, nurse-to-patient ratios and require Level 2 and Level 3 doctors to hold a Doctorate of Medicine or a Doctorate of the National Board in intensive care.

Subscribe to enjoy similar stories.India’s weight-loss frenzy is under the scanner, with the blockbuster drug semaglutide facing fresh scrutiny after hundreds of suspected complications were flagged, said two government officials in the know, with medical experts noting that about half the users report some side-effects. The ongoing review could lead to tighter norms, including label changes, safety warnings and stricter prescription rules.Amid the hype surrounding these glucagon-like peptide-1 (GLP-1) receptors' efficacy for weight loss, the government has documented around 400 reports of adverse drug reactions (ADRs) potentially linked to the medication that is now being clinically evaluated, the officials said.

Subscribe to enjoy similar stories.The Centre plans to mandate that doctors and specialists display their consultation fees in English and regional languages, along with their qualifications and registration numbers, according to two government officials and documents reviewed by Mint.The plan also involves mandating a minimum consultation room size of 70 square feet and requiring clinics to stock emergency drugs, including aspirin, adrenaline injections, isosorbide dinitrate for angina (chest pain), diazepam for anxiety and seizures, dexamethasone for inflammatory conditions and severe allergies, and atropine for slow heart rate, among others, through amendments to the Clinical Establishments Rules.The plan covers a broad range of facilities, outlining minimum standards for consultation clinics, clinics with dispensaries, establishments with diagnostic support services, and those offering observation or short-stay care, as well as collection centres and mortuaries.To be sure, there are approximately 43,486 private healthcare facilities and 1,386,136 doctors in India, according to the National Medical Commission (NMC).Every clinic and polyclinic must display a prominent signboard at its entrance, showing operating hours and a clear list of services offered, according to the draft Clinical Establishments Amendment Rules, 2026, reviewed by Mint.The draft calls for strict spatial requirements to ensure patient safety and comfort. For a standard consultation clinic, the government has proposed a minimum carpet area of 35 square feet for the reception and waiting area.

Subscribe to enjoy similar stories.Mumbai: India’s second-biggest overseas acquisition was stitched together over three months of near-daily negotiations between the bidder, the seller and their bankers, said a banker aware of the details behind the transaction.Mumbai-based Sun Pharmaceutical Industries Ltd on Monday said in an exchange filing it will acquire US-headquartered Organon & Co for about $11.75 billion. This is the largest overseas deal by an Indian company since Tata Steel acquired UK-based Corus Group for $12 billion in 2007.The deal was always pitched at around $12 billion from both sides, with negotiations neither exceeding nor materially falling from that level, the person cited above said on the condition of anonymity.“The deal was out in the market sometime late 2025, and Sun was very interested because it gave them access to more than 100 countries across the world and also complemented the product suite,” said the banker.

Subscribe to enjoy similar stories.India is planning a sweeping overhaul of its drug regulatory system by unifying central and state licensing, approvals, and compliance into a single digital platform, according to two government officials and documents reviewed by Mint.At the centre of the plan is a proposed interoperable Digital Drugs Regulatory System (DDRS) being developed by the Central Drugs Standard Control Organisation (CDSCO). The regulator is preparing to invite proposals from IT services firms to build and run the platform, the documents show.The DDRS is designed to streamline complex processes—from registration and clinical trial approvals to import-export licensing and supply chain traceability—by bringing central and state regulators, laboratories, and allied agencies onto a unified, real-time digital architecture.States have been asked to review the proposed framework and provide feedback, the first person cited above said, requesting anonymity.

Subscribe to enjoy similar stories.India's apex drugs regulator has directed state governments to enforce uniform medicine standards to eliminate regional variability in regulatory compliance.In its February directive, reviewed by Mint, the Central Drugs Standard Control Organization (CDSCO), chaired by the Drugs Controller General of India, Rajeev Singh Raghuvanshi, wrote that concerns have been raised regarding inconsistencies in the enforcement of drug standards across the country, low conviction rates in cases of drug adulteration, and the need for stringent scrutiny of adulteration in imported pharmaceutical products."All states are advised to take proactive measures to effectively address the issues. You are also requested to strengthen the necessary infrastructure, including the provision of adequate manpower under the State Health Regulatory Excellence Index (SHRESTH),” the letter said.The development assumes significance for India’s $50 billion pharmaceutical market, which is facing a quality crisis after Indian-manufactured cough syrups were linked to over 140 deaths globally, including in Gambia, Uzbekistan, and Cameroon, due to ethylene glycol poisoning.Mint's emailed queries to the health ministry spokesperson and the DCGI office on 15 April remained unanswered.

Subscribe to enjoy similar stories.A 34-year-old Pune woman, diagnosed with polycystic ovary syndrome (PCOS) as a teenager, saw her first natural menstrual cycle in February—six months after starting Mounjaro for weight management. This spotlights a broader shift, as more women with the condition turn to GLP-1 (glucagon-like peptide-1) drugs for metabolic relief and, in some cases, improved fertility.The trend is accelerating across India, doctors said, even though these drugs are not officially approved for treating PCOS and are prescribed primarily for type-2 diabetes and obesity.“I’ve had PCOS since I can remember, and with that comes infertility,” she told Mint, requesting her name be withheld to protect her privacy.

Subscribe to enjoy similar stories.New Delhi: India is planning to overhaul its pharmaceutical storage rules for vaccines and biological products, as gaps in the regulatory framework have frequently led to drugs being stored under improper temperature conditions, potentially compromising their efficacy, according to two government officials and documents reviewed by Mint.The plan is to define and classify these medications into two group— thermostable or those that can survive high temperatures, and thermolabile, or those that cannot, to ensure medicines, including insulin and vaccines are handled with scientific precision throughout the supply chain. Currently, the Drugs and Cosmetics Act, 1940, lacks these specific classifications.While Schedule P of the Drugs Rules, 1945 provides general storage instructions such as ‘cold place’ for temperatures not exceeding 8 degrees Celsius, there has been no comprehensive, science-based list to guide manufacturers and drug inspectors.

Subscribe to enjoy similar stories.The government is revamping Ayurveda institutes, modernizing hospitals, upgrading research and globalizing traditional systems for medical tourism, as announced in Union Budget 2026.Morbidity codes for Ayurveda, Siddha and Unani systems have now been incorporated into the World Health Organisation’s International Classification of Diseases, and an index for the International Classification of Health Interventions through traditional medicines has also been agreed upon.This could, in time, position India as a hub for Ayurvedic and traditional medicine treatments.But can treatments at AYUSH centres be claimed in a cashless manner like allopathic procedures?The answer lies in how insurers currently interpret such treatments.Health insurance policies state that “inpatient treatments under Ayurveda, Yoga & Naturopathy, Unani, Siddha, and Homeopathy are covered.”For cashless claims, treatments must be taken at network hospitals. Reimbursement claims — where patients pay first and submit bills later — can be more complicated.Given the early stage of such claims, insurers and third-party administrators (TPAs) are balancing two competing pressures: honouring AYUSH claims as mandated by the government and Insurance Regulatory and Development Authority of India (Irdai), while protecting portfolios from treatments that are not medically mandatory but taken for rest, restoration or wellness — where billing limits may not be clearly defined.The ecosystem for cashless claims is still evolving.

Subscribe to enjoy similar stories.New Delhi: Struggled with illegible and poorly-placed labels for medicines? There may be help on way, as the apex drugs regulator is set to tighten scrutiny of how critical information, such as medicine names and expiry dates, is printed on the packaging, according to two government officials and documents reviewed by Mint.The move by the Central Drugs Standard Control Organisation (CDSCO) aims to curb medication errors and improve patient safety in India's $50 billion pharmaceuticals market.According to the plan in the works, the CDSCO and state regulators will step up plant inspections and issue targeted instructions to drug inspectors with a focus on visibility, durability and placement of key information.Following complaints, the apex regulator had appointed a committee that identified a significant gap in the variability of medicine labelling implementation at the manufacturing level.Consumers' complaints ranged from the packaging information being illegible due to a host of reasons to the demand for the medicine name being printed across the package and for a universally-recognized symbol on generic medicines to distinguish them from branded ones.The CDSCO set up a sub-committee in July 2025, chaired by the drugs controller of Telangana, with drugs controllers of Kerala, Odisha and representatives of HLL Lifecare Ltd, the deputy drugs controller of Hyderabad zone and Indian Drug Manufacturers’ Association (IDMA) officials as members.In its report, this panel said the CDSCO and state licensing authorities "may issue suitable advisories or internal instructions to GMP inspectors to ensure focused scrutiny of labelling practices, including visibility, durability and placement of

NEW DELHI: India plans to restrict the testing of vaccines and specialized biological products exclusively to government-controlled laboratories to maintain quality standards, according to two government officials and documents reviewed by Mint. This new approach will affect private laboratory operators and the pharmaceutical manufacturers that rely on them for faster testing turnaround times.Under the existing rules, private labs are allowed to test specified drugs including vaccines and biologicals.

In a first, India plans to publicly disclose findings from inspections of drug manufacturing units, marking a shift towards greater transparency and quality monitoring, according to two government officials and documents reviewed by Mint.According to the proposal being discussed, the country’s apex drugs regulator, Central Drugs Standard Control Organization (CDSCO), will publish details of inspected firms and audit recommendations on its website, as India's pharmaceuticals sector faces heightened scrutiny over quality.The plan assumes significance for the country's $50 billion pharmaceutical market in the backdrop of Indian-manufactured cough syrups being linked to over 140 deaths in countries, including Gambia, Uzbekistan and Cameroon, due to ethylene glycol poisoning.The office of Drugs Controller General of India (DCGI), headed by Rajeev Raghuvanshi, conducts these risk-based inspections (RBI) to ensure compliance with regulatory requirements under the Drugs and Cosmetics Act and Rules.“It has been desired that CDSCO may examine the feasibility of displaying brief details of firms inspected under RBI along with the recommendations of the inspection team, after due consideration of legal implications," according to the documents reviewed by Mint. "During such inspections, inspection teams make observations and recommendations based on risk assessment.

Mint explains what changes.The rules make it compulsory to segregate waste at source into four categories: wet, dry, sanitary, and special care waste. Wet waste—such as kitchen waste, vegetable and fruit peels, meat, and flowers—is to be composted or processed through bio-methanation at nearby facilities.

NEW DELHI: Patients may no longer be forced to buy an entire strip of tablets or capsules when they need only one or a few of them.India’s apex drugs regulator plans to introduce a rule mandating pharmacies to dispense the exact number of tablets and capsules prescribed by allowing the sale of cut strips, according to two government officials and documents reviewed by Mint.Many drugs, including antibiotics, are typically sold in strips of 10 or 15 tablets or capsules when patients may require only five tabs. A proposal on dispensing exact prescription quantities of strip-packed medicines was discussed at a meeting chaired by the Drugs Controller General of India on 20 March.This regulatory shift is significant for India's $50 billion pharmaceutical industry and perhaps even more so for the retail pharmacy market, which was valued at $20 billion-27 billion in 2024.

Delhi-based Deepak Kakkar didn’t think of caregiving as a financial line item until it became one. When his septuagenarian father’s health declined due to liver cirrhosis in 2024, the immediate concern was medical treatment. But within weeks, he could see his monthly household budget change completely.